Compare PAHC & FTRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PAHC | FTRE |
|---|---|---|
| Founded | 1946 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.3B |
| IPO Year | 2014 | 2023 |
| Metric | PAHC | FTRE |
|---|---|---|
| Price | $32.76 | $16.07 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 4 | 9 |
| Target Price | ★ $41.25 | $14.06 |
| AVG Volume (30 Days) | 406.7K | ★ 1.1M |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | ★ 0.91% | N/A |
| EPS Growth | ★ 1883.33 | N/A |
| EPS | ★ 1.90 | N/A |
| Revenue | $833,350,000.00 | ★ $2,723,400,000.00 |
| Revenue This Year | $17.03 | N/A |
| Revenue Next Year | $3.82 | $3.09 |
| P/E Ratio | $17.07 | ★ N/A |
| Revenue Growth | ★ 4.12 | 1.00 |
| 52 Week Low | $22.85 | $4.46 |
| 52 Week High | $60.08 | $18.67 |
| Indicator | PAHC | FTRE |
|---|---|---|
| Relative Strength Index (RSI) | 36.35 | 64.49 |
| Support Level | N/A | $15.66 |
| Resistance Level | $34.98 | $16.20 |
| Average True Range (ATR) | 1.55 | 0.97 |
| MACD | 0.56 | 0.14 |
| Stochastic Oscillator | 60.01 | 68.04 |
Phibro Animal Health Corp operates as a diversified animal health and mineral nutrition company. It develops, manufactures, and markets products for a range of food animals comprising poultry, swine, beef and dairy cattle, and aquaculture. The product portfolio of the company includes animal health products such as antibacterials, anticoccidials, nutritional specialty products and vaccines, and mineral nutrition products. The company operates through three segments, Animal Health, Mineral Nutrition, and Performance Products, of which key revenue is derived from the Animal Health segment which relates to the development, manufacturing, and marketing of antibacterials, nutritional specialty products, and vaccines. The entity sells its products in the U.S. and other international countries.
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion.